Nautilus Biotechnology is trading at $1.90, down -12.04%, with no company-specific news clearly explaining the decline.
- The company announced it will report third-quarter results on October 27; that scheduled announcement does not establish a cause for today’s move.
- Broader risk-off sentiment may be a backdrop: the Nasdaq is down 0.92% amid inflation and technology-stock concerns. The supplied biotech-sector measure is positive, so sector weakness does not explain the drop.